other material
confidence high
sentiment positive
materiality 0.85
Fractyl's Revita hits REMAIN-1 six-month endpoint, cutting post-GLP-1 weight regain 80% vs 67% sham (p=0.0023)
FRACTYL HEALTH, INC.
- Six-month co-primary endpoint met in mITT (N=308): Revita maintained ~80% of GLP-1-induced weight loss vs 67% for sham; mean weight regain 5.1% vs 8.2% (p=0.0023).
- 32% of Revita participants were weight-stable or lost more weight at 6 months post-GLP-1 discontinuation vs 18% for sham (post hoc; nominal p=0.020).
- Dose response: 12-18 cm duodenal ablation cut regain 43% vs sham (4.7% vs 8.2%; n=107); 20 cm or more cut regain 53% (3.8%; n=47).
- Safety: no device- or procedure-related serious adverse events or deaths; no unanticipated device effects at the Sept. 24, 2026 cut-off; 94% of related AEs were within 7 days.
- Plans FDA De Novo submission in late Q4 2026, 12-month data plus second co-primary endpoint in Q1 2027, CPT code 1122T effective Jan 1, 2027, potential U.S. launch early 2028.